IceCure Medical Ltd ICCM

Company Overview

IceCure Medical Ltd. is an Israel-based medical device company focused on minimally invasive cryoablation technology for the treatment of tumors and other tissue-related conditions. The company operates within the medical technology and interventional oncology sectors, with its primary commercial platform centered on liquid nitrogen–based cryoablation systems designed to destroy tumors through controlled freezing. IceCure’s flagship technology platform, ProSense®, is used in procedures involving breast, kidney, lung, liver, and bone tumors, among other indications. The company generates revenue primarily through the sale of cryoablation systems, disposable probes, and related procedural products and services.

IceCure’s principal customer base includes hospitals, surgical centers, oncology clinics, and interventional radiology practitioners across multiple international markets. The company has positioned itself around minimally invasive alternatives to traditional surgical oncology procedures, particularly in breast tumor treatment for patients seeking reduced recovery times and less invasive intervention. Founded in 2006 and headquartered in Caesarea, Israel, IceCure expanded through clinical development programs, regulatory approvals in multiple jurisdictions, and partnerships with healthcare providers and distributors. Public filings and company disclosures indicate that the company’s strategic focus has increasingly emphasized breast cancer applications and broader adoption of office-based cryoablation procedures.